NCT05784467

Brief Summary

The goal of this clinical trail is to test the developed eMPrISe study in HIV-negative, adult, Latino men who have sex with men (MSM) who use non-injection substances. The main questions it aims to answer are:

  • Can participation in the developed eMPrISe study reduce methamphetamine ('meth') use risk?
  • Can participation in the developed eMPrISe study improve preexposure prophylaxis (PrEP) cascade progression? Participants will participate in 12 weekly modules that: (1) build critical thinking skills, (2) identify and discuss the link between oppression and harmful behaviors, (3) take action, (4) voice and validate feelings and experiences, and (5) share knowledge and resources.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
16mo left

Started Apr 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress5%
Apr 2026Aug 2027

First Submitted

Initial submission to the registry

March 13, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 27, 2023

Completed
3.1 years until next milestone

Study Start

First participant enrolled

April 15, 2026

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Expected
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2027

Last Updated

February 19, 2026

Status Verified

February 1, 2026

Enrollment Period

4 months

First QC Date

March 13, 2023

Last Update Submit

February 17, 2026

Conditions

Methamphetamine AbuseHivSocial Stigma

Keywords

MethamphetaminePreexposure prophylaxisIntersectional Stigma

Outcome Measures

Primary Outcomes (2)

  • Methamphetamine use risk

    Assessed using the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) Scores range from 0 - 39, where higher scores indicate higher risk.

    3 Months

  • PrEP cascade progression

    Assessed using the Motivational PrEP Cascade Ordinal outcome including: 1= PrEP pre-contemplation, 2= PrEP contemplation, 3=PrEParation, 4=PrEP Action \& Initiation, 5=PrEP Maintenance

    3 Months

Secondary Outcomes (3)

  • Resistance

    3 Month

  • Resilience

    3 Month

  • Coping

    3 Month

Study Arms (2)

English

OTHER

Participants in the English arm will receive the eMPrISe intervention materials in English.

Behavioral: Methamphetamine, PrEP, and Intersectional Stigma (eMPrISe) study

Spanish

OTHER

Participants in the English arm will receive the eMPrISe intervention materials in Spanish.

Behavioral: Methamphetamine, PrEP, and Intersectional Stigma (eMPrISe) study

Interventions

Methamphetamine, PrEP, and Intersectional Stigma (eMPrISe) studyBEHAVIORAL

Group behavioral intervention with 12 weekly sessions lasting 2 hours focusing on coping, resistance, and resilience.

EnglishSpanish

Eligibility Criteria

Age18 Years+
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsCisgender men
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • + years of age
  • cisgender male
  • self-identify as Latino or Hispanic
  • fluent in English or Spanish
  • any sexual activity with men in the past 12 months
  • HIV-negative
  • moderate methamphetamine use risk (as determined by the the ASSIST assessment)
  • experience of intersectional stigma within their social network in the past 12 months
  • willing to provide written informed consent

You may not qualify if:

  • N/A

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Acquired Immunodeficiency SyndromeSocial Stigma

Interventions

Methamphetamine

Condition Hierarchy (Ancestors)

HIV InfectionsBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesSocial BehaviorBehavior

Intervention Hierarchy (Ancestors)

AmphetaminesPhenethylaminesEthylaminesAminesOrganic Chemicals

Central Study Contacts

Angel B Algarin, PhD, MPH

CONTACT

(602) 496-0845angel.algarin@asu.edu

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Each group will receive the same intervention components, but one group will be facilitated in English and the other, Spanish.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 13, 2023

First Posted

March 27, 2023

Study Start

April 15, 2026

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

August 31, 2027

Last Updated

February 19, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share